Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California


Recent News and Articles on the Keywords: hiv + peptide + may  Related to the article below (Last Update: 12/1/2008)

 News results: Standard Version | Text Version | Image Version Results 1 - 5 of about 19 for hiv peptide may. (0.14 seconds) 
Recent
Archives
  • All dates
  • 2007
  • 2006
  • 2005
  • 2004
  • 1999-2003

 Sorted by relevance   Sort by date   Sort by date with duplicates included 
Other News To Note
TMCnet - Nov 26, 2008
That peptide demonstrated in recently completed initial in vitro and in vivo studies a potential to treat inflammatory diseases, among other indications. ...
Ambrilia Initiates Plan Aiming to Significantly Reduce its ...
MarketWatch - Nov 19, 2008
Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, ...
Scientists scratch heads over why we itch
The Miami Herald, FL - Nov 17, 2008
Chronic itch may result from kidney, liver or blood disease, HIV, shingles, eczema or many other causes. Scientists aren't sure why scratching helps relieve ...
Ambrilia Reports Third Quarter 2008 Results
MarketWatch - Nov 14, 2008
... a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights ...TSE:AMB - OTC:CMTX
Rodman & Renshaw Annual Global Investment Conference Presenter ...
TMC Net, CT - Nov 7, 2008
Most notably is its CT-112 product, an anti- inflammatory peptide, that has shown promise in pre-clinical testing, and for which the Company is currently ...RODM
Source: Google News


 

Recent News and Articles on the Keywords: peptide + block + hiv  Related to the article below (Last Update: 8/5/2008)

Viral Cloaking Device -- How Viruses Evade The Immune System
Science Daily (press release) - Jul 18, 2008
The peptide is obscured from killer cells by yet another shield, Yang says. In a trait it shares with HIV proteins, HCMV's UL18 covers itself with ...
Roche posts very good results: strong market outperformance ...
Business-News, Switzerland - Jul 20, 2008
R1583 (taspoglutide, BM 51077, licensed from Ipsen), the first once-weekly human glucagon-like peptide-1 (GLP-1) analogue, is being developed by Roche for ...
Source: Google News

CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. … -
MR Ruff, BM Martin, EI Ginns, WL Farrar, CB Pert - FEBS Lett, 1987 - ncbi.nlm.nih.gov
Click here to read CD4 receptor binding peptides that block HIV infectivity cause
human ... The octapeptide Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr (peptide T) and two ...

… -sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-enhanced Epitope of the HIV-1 … -
M Farzan, N Vasilieva, CE Schnitzler, S Chung, J … - Journal of Biological Chemistry, 2000 - ASBMB
... S-peptide but not the C-peptide; thus, the sulfate moieties on the S-peptide are
critical for the ability of this peptide to block CCR5-dependent HIV-1 entry. ...

… immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in … -
N Yahi, JM Sabatier, S Baghdiguian, F Gonzalez- … - Journal of Virology, 1995 - pubmedcentral.nih.gov
... synthetic multibranched peptides derived from the consensus sequence of the
HIV-1 V3 loop block HIV-1 infection in HT-29 cells. The most active peptide was ...

Peptide and non-peptide HIV fusion inhibitors -
S Jiang, Q Zhao, AK Debnath - Curr Pharm Design, 2002 - ingentaconnect.com
... 2) Although addition of N-peptide to C-peptide decreases C-peptide-mediated
anti-HIV activity, N-peptide might never completely block the HIV fusion inhibitory ...

Contribution of Human a-Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral Factor -
L Zhang, W Yu, T He, J Yu, RE Caffrey, EA Dalmasso … - Science, 2002 - sciencemag.org
... are commercially available: -defensin 1 and 2 (American Peptide Co., Sunnyvale,
CA ... termed retrocyclin, has recently been demonstrated to block HIV-1 infection ...

… Human Immunodeficiency Virus (HIV)-Specific T Cells and Can Block HIV Replication after Initiation … -
S Le Borgne, M Fevrier, C Callebaut, SP Lee, Y … - Journal of Virology, 2000 - Am Soc Microbiol
... peptide. Following acute infection of CEM cells with an X4 strain of HIV-1,
EBV-specific CTL line supernatant containing HIV-suppressive activity did not block ...

Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: Implications for the … -
JK Judice, JYK Tom, W Huang, T Wrin, J Vennari, CJ … - Proceedings of the National Academy of Sciences, 1997 - National Acad Sciences
... Other agents that block HIV-1 infectivity by binding to this ... the C-terminal boundary
of the HIV 1 fusion ... CP Hill, and MS Kay Potent D-peptide inhibitors of HIV ...

Apelin peptides block the entry of human immunodeficiency virus (HIV) -
MX Zou, HY Liu, Y Haraguchi, Y Soda, K Tatemoto, H … - FEBS Letters, 2000 - Elsevier
... bind to the APJ receptor, failed to block HIV entry, indicating that specific binding
to this receptor may be required for an apelin-related peptide to block ...

Liposome destabilization induced by the HIV-1 fusion peptide Effect of a single amino acid … -
FB Pereira, FM Goni, JL Nieva - FEBS Letters, 1995 - Elsevier
... To our knowledge, this is the first time that a substitution in the HIV-I fusion
peptide, known to block gp41 fusion activity, is related to the loss of a ...

… Virus-1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide -
I Mun~ oz-Barroso, S Durell, K Sakaguchi, E … - The Journal of Cell Biology, 1998 - Rockefeller Univ Press
... are different binding sites for this peptide on gp41 ... we have only observed binding
to HIV-1 envelope ... position the peptides would sterically block the regular ...

Source: Google Scholar
 
 

Study: Primate peptide may block HIV

ORLANDO, Fla., Aug. 9 (UPI) -- U.S. scientists say they've determined a defense peptide found in primates might block some human HIV transmissions.

As primates evolved 7 million years ago, the more advanced species stopped making a protein that University of Central Florida researchers believe can effectively block the HIV-1 virus from entering and infecting blood cells.

HIV-1 often mutates quickly to overcome antiviral compounds designed to prevent infections. But a team led by Associate Professor Alexander Cole of UCF's Burnett College of Biomedical Sciences has demonstrated that, during a 100-day period, the virus develops only weak resistance to retrocyclin, a defense peptide still found in monkeys and lower primates.

 

If additional laboratory tests demonstrate only weak resistance, Cole will study how retrocyclin could be developed into a drug designed to prevent the HIV virus from entering human cells.

"If we could develop retrocyclin in plants and produce enough of the drug cheaply, we could potentially save a lot of lives," Cole said.

Cole was recently awarded $4 million in grants from the National Institutes of Health for the HIV-1 research and similar studies.

Cole's findings appeared in the June 1 issue of The Journal of Immunology.

 

 
Google
Web www.iconocast.com
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page